Trimetazidine in Practice: Review of the Clinical and Experimental Evidence

American Journal of Therapeutics
Csaba A Dézsi

Abstract

All of the following traditional agents for the management of stable angina pectoris include the symptomatic treatment with heart rate-lowering agents such as β-blockers or non-dihydropyridine Ca-channel blockers, or ivabradine-the first selective sinus node If channel inhibitor-vasodilatators and preventive use of angiotensin-converting enzyme inhibitors affect the parameters of circulation directly. Trimetazidine exerts its anti-ischemic action by modulating cardiac metabolism without altering the hemodynamic functions, therefore represents an excellent complementary potential to the conventional angina treatment. It has a beneficial effect on the inflammatory profile and endothelial function and shows diverse benefits by reducing the number and the intensity of angina attacks and improving the clinical signs and symptoms of myocardial ischemia given as monotherapy as well as combined with other antianginal agents. Patients undergoing coronary revascularization procedures or with comorbid left ventricular dysfunction and diabetes mellitus also benefit from the protective effects of trimetazidine.

References

Feb 1, 1996·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·P J JacksonH R Schwietert
Dec 19, 2002·Current Medical Research and Opinion·Lech PolońskiKrzysztof Wilczek
Nov 11, 2003·Current Medical Research and Opinion·Mario Marzilli
Nov 5, 2005·Thérapie·José-Félix Martí MassóAdolfo López de Munain
Feb 25, 2006·The Tohoku Journal of Experimental Medicine·Filiz KuralayOzhan Goldeli
Aug 29, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Ihsan IskesenHayrettin Sirin
Apr 26, 2007·European Heart Journal·Romualdo BelardinelliAugusto Purcaro
Apr 14, 2010·Expert Opinion on Emerging Drugs·Stanley F FernandezWilliam E Boden
Feb 4, 2011·Cardiovascular Research·Vincenzo LionettiFabio A Recchia
Jul 15, 2011·Diabetes Technology & Therapeutics·Sunil K KotaKirtikumar D Modi
Aug 3, 2011·Arquivos brasileiros de cardiologia·Gerez Fernandes MartinsAlberto Valência
Sep 22, 2011·Current Pharmaceutical Design·Tomohisa NagoshiSeibu Mochizuki
Dec 14, 2011·Journal of Clinical Pharmacology·Latif OzbayDilek Erol
Mar 3, 2012·Journal of the American College of Cardiology·Lei ZhangJunbo Ge
Jul 14, 2012·Arquivos brasileiros de cardiologia·Gerez Fernandes MartinsBarbara Jessen
Mar 5, 2013·Heart Failure Reviews·Adriana Adameova, Naranjan S Dhalla
Jan 5, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Csaba András Dézsi

❮ Previous
Next ❯

Citations

Feb 22, 2017·Advances in Therapy·Maria Glezer, UNKNOWN CHOICE-2 study investigators
Jul 4, 2018·British Journal of Pharmacology·Binh Yen NguyenWei Liu
Aug 22, 2020·The Journal of Physiology·Tanya SolomonHelena Viola
Feb 16, 2019·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·B O van DrielJ van der Velden
Jul 3, 2020·Frontiers in Physiology·J SnyderP Y Sato
Apr 1, 2020·Frontiers in Cardiovascular Medicine·Alessandra MurabitoAlessandra Ghigo
Nov 12, 2020·Journal of the American Heart Association·Edgar E NolletJolanda van der Velden
Jan 30, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Jingjing ZhangHongjun Yang
May 14, 2021·Luminescence : the Journal of Biological and Chemical Luminescence·Fathalla BelalHytham Ahmed
Feb 1, 2017·Terapevticheskiĭ arkhiv·S G Kanorskii, N V Smolenskaya

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
coronary artery bypass
sedation

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

© 2022 Meta ULC. All rights reserved